#Acet

StockTitan

@stocktitan.net

3 days ago

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Adicet Bio (Nasdaq: ACET) reported Q4 and full‑year 2025 results and clinical progress on prula‑cel and ADI‑212. Key operational updates include FDA Fast Track designation for prula‑cel, FDA alignment enabling outpatient dosing for LN and SLE, strong enrollment momentum with clinical updates expected in 1H and 2H 2026, and a planned regulatory filing for ADI‑212 in 3Q/2026.Financially, 2025 net loss was $116.8M, cash and short‑term investments were $158.5M at year‑end, and the company raised $74.8M net in October 2025; cash runway is expected into H2 2027.

#ACET Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

www.stocktitan.net/news/ACET/adicet-bio-rep...

Market Wire News

@marketwirenews.com

1 month ago

Just In: ( NASDAQ: #ACET ) Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

@Eustat

@handle.invalid

2 months ago

El #PIB de la C.A. de Euskadi ha crecido un 2,3 % en el año 2025 y el empleo ha crecido un 1,4%, ambos con respecto al año anterior.

🔗 https://f.mtr.cool/gfihhehlxo

@ekonomiaejgv.bsky.social 
#ACET

AfricTivistes

@africtivistes.bsky.social

2 months ago

🇲🇷 AfricTivistes CitizenLab Mauritania has launched a training on digital citizenship & civic leadership.

🛠️ The training uses the #ACET Toolkit, designed by #AfricTivistes to help trainers easily replicate the programme and reach more young people across Africa.

🔗 africtivistes.com/en/acet-tool...

StockTitan

@stocktitan.net

2 months ago

Adicet Bio Announces Reverse Stock Split Adicet Bio (Nasdaq: ACET) announced a one-for-16 reverse stock split of common stock, effective 12:01 a.m. ET on December 30, 2025, with trading on a split-adjusted basis beginning at the open on December 30, 2025.The reverse split will combine every sixteen issued shares into one, reducing outstanding shares from approximately 153.3 million to approximately 9.6 million. Authorized shares remain at 300,000,000, which the company says increases the number of shares available for future issuance. Proportional adjustments will be made to equity awards, options, conversions, and pre-funded warrants; fractional shares will be settled for cash. The company intends the split to help regain compliance with Nasdaq's minimum bid price requirement.

#ACET Adicet Bio Announces Reverse Stock Split

www.stocktitan.net/news/ACET/adicet-bio-ann...

StockTitan

@stocktitan.net

4 months ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates Adicet Bio (NASDAQ: ACET) reported Q3 2025 results and clinical updates on November 5, 2025. The company announced positive preliminary Phase 1 safety and efficacy data for ADI-001 in seven lupus nephritis (LN) and SLE patients, including rapid SLEDAI-2K and PGA reductions, improved renal function with three complete renal responses and DORIS remissions, emergence of a naïve B cell repertoire, and no Grade 2+ CRS or ICANS as of the August 31, 2025 cut-off. Adicet plans an FDA meeting in 1Q/2026 and anticipates starting a potentially pivotal ADI-001 study in 2Q/2026. The company raised $74.8M net in October, extending cash runway into 2H/2027. Q3 net loss was $26.9M and cash on Sept 30 was $103.1M.

#ACET Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/ACET/adicet-bio-rep...

StockTitan

@stocktitan.net

5 months ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) Adicet Bio (Nasdaq: ACET) announced the first patient has been dosed in its Phase 1 trial of ADI-001 for treatment-refractory rheumatoid arthritis (RA) on October 16, 2025. The program is enrolling across seven autoimmune conditions and will test two conditioning regimens: cyclophosphamide alone and cyclophosphamide plus fludarabine. Preliminary clinical data are expected in 2H/2026. The company cited prior promising safety and efficacy findings for ADI-001 in lupus nephritis and systemic lupus erythematosus as encouragement for broader autoimmune potential.

#ACET Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

www.stocktitan.net/news/ACET/adicet-bio-ann...

@Eustat

@handle.invalid

5 months ago

🔈 El #PIB de la C.A. de Euskadi creció 📈 2,2 % y el empleo 📈 1,4 % (13.000 puestos) en el 3º trimestre de 2025, respecto al mismo periodo del año pasado.
🔈 Frente al 2º trimestre: el PIB 📈0,4 % y el empleo 📈0,2 %

🔗 https://f.mtr.cool/qnbfintxvl

#ACET

StockTitan

@stocktitan.net

5 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering REDWOOD CITY, Calif.& BOSTON---- Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors,...

#ACET Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

www.stocktitan.net/news/ACET/adicet-bio-inc...

StockTitan

@stocktitan.net

5 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) Adicet Bio (Nasdaq: ACET) reported positive preliminary Phase 1 data for ADI-001 in lupus nephritis (LN) and systemic lupus erythematosus (SLE) as of the August 31, 2025 data cut-off. All seven evaluable patients (five LN, two SLE) showed rapid, sustained SLEDAI-2K and PGA score reductions and immune reset signals after a single dose. All five LN patients achieved renal responses (three complete responses with DORIS remissions, two partial responses), with responses ongoing. ADI-001 was generally well tolerated (no SAEs, no ICANS, two Grade 1 CRS, one Grade 1 infection). More than 25 sites are open; Adicet plans an FDA meeting in 1Q/2026 and anticipates a pivotal study start in 2Q/2026.

#ACET Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

www.stocktitan.net/news/ACET/adicet-bio-ann...

@Eustat

@handle.invalid

5 months ago

El #PIB de la C.A. de Euskadi creció 📈 2,2% y el empleo 📈 1,4% (14.035 puestos) en el 2º trimestre de 2025, respecto al mismo periodo del año pasado.
Frente al 1er trimestre: el PIB 📈0,5 % y el empleo 📈0,3 %

🔗 https://f.mtr.cool/znuisnhzga

#ACET

UVic Faculty of Social Sciences

@uvicsocialsciences.bsky.social

6 months ago

UVic researcher named lead author for IPCC report - Social Sciences - University of Victoria Inspired by and honouring place, we are a community-minded, globally engaged university where we transform ideas into meaningful impact.

Congratulations to Katya Rhodes, #uvic public administration @uvic.ca @uvicresearch.bsky.social @picscanada.bsky.social #ACET www.uvic.ca/socialscienc...

NC_dessinateur

@nc-dessinateur.bsky.social

6 months ago

#acetamipi #acet #acetoomu rooh et puis merde.

Vieux dessin qu'il est bon de ressortir.

Par ici la boutique : ncdessinateur-fr.sumupstore.com?fbclid=IwQ0x...

StockTitan

@stocktitan.net

7 months ago

Adicet Bio Expands Autoimmune Disease Trial: First Systemic Sclerosis Patient Receives Novel T Cell Therapy New milestone in ADI-001 clinical trial targeting multiple autoimmune conditions. Preliminary data expected in 2H 2025. Learn about this potential breakthrough therapy.

#ACET Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

www.stocktitan.net/news/ACET/adicet-bio-ann...

@Eustat

@handle.invalid

8 months ago

El #PIB de la C.A. de Euskadi 📈 creció 2,2% y el empleo 📈 1,4% en el 2º trimestre de 2025. Respecto al primer trimestre, el PIB aumentó un 0,5% y el empleo un 0,3%. Se han creado más de 13.000 puestos de trabajo. 

🔗 https://f.mtr.cool/rbqkcyljas

#ACET

StockTitan

@stocktitan.net

10 months ago

Adicet Bio Advances Two Breakthrough Therapies: Key Clinical Data Coming in 2025 for Lupus and Cancer Programs $150.4M cash runway into 2026 as Adicet Bio advances dual clinical programs. Critical Phase 1 data expected for lupus and cancer therapies. See trial updates.

#ACET #APRE Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/ACET/adicet-bio-rep...

Jason Who

@akajasonwho.bsky.social

11 months ago

Ateneo (ADMU) results are out! #ACET

StockTitan

@stocktitan.net

1 year ago

Can Adicet Bio's $176M War Chest and Fast Track Status Transform Autoimmune Treatment? Biotech firm reports solid financials with extended cash runway and advances gamma delta T cell therapy programs, securing FDA Fast Track Designation for ADI-001.

#ACET Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

www.stocktitan.net/news/ACET/adicet-bio-rep...

StockTitan

@stocktitan.net

1 year ago

Can Adicet's Novel CAR T Therapy Revolutionize Renal Cancer Treatment? New Data Coming Adicet's ADI-270 shows improved efficacy over conventional treatments in preclinical studies, advancing to Phase 1/2 trials for renal cell carcinoma patients.

#ACET Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

www.stocktitan.net/news/ACET/adicet-announc...

StockTitan

@stocktitan.net

1 year ago

Adicet's Systemic Sclerosis Therapy Earns Critical FDA Fast Track Status - What This Means for Patients Adicet's gamma delta T cell therapy receives expedited review pathway, potentially accelerating development for this serious autoimmune disease with options.

#ACET Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

www.stocktitan.net/news/ACET/adicet-bio-rec...

StockTitan

@stocktitan.net

1 year ago

Revolutionary Lupus Treatment Gets FDA Fast-Track: Adicet's ADI-001 Could Transform Patient Care Adicet Bio secures FDA Fast Track Designation for ADI-001, accelerating development of their innovative therapy for systemic lupus erythematosus treatment.

#ACET Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

www.stocktitan.net/news/ACET/adicet-bio-rec...

@godsmackinbb.bsky.social

1 year ago

#acet #freight

StockTitan

@stocktitan.net

1 year ago

Adicet Bio Advances First Gamma Delta CAR T Cell Therapy for Solid Tumors, Expands Autoimmune Trial Adicet Bio doses first patient in ADI-270 solid tumor trial while expanding ADI-001 study across six autoimmune diseases. Both therapies received FDA Fast Track Designation.

#ACET Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

www.stocktitan.net/news/ACET/adicet-bio-pro...

StockTitan

@stocktitan.net

1 year ago

Adicet Bio Launches Phase 1 Trial of Novel Gamma Delta T Cell Therapy for Advanced Kidney Cancer Adicet Bio initiates groundbreaking Phase 1 study of ADI-270, an innovative cell therapy targeting advanced renal cell carcinoma, with data expected in 2025.

#ACET Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

www.stocktitan.net/news/ACET/adicet-bio-ann...

Aat

@aat2024.bsky.social

1 year ago

Welcome to ACTBINGO.COM
actbingo.com

#ACT #Acet #ACTWarriors #iHoldACT #ACTisThePeople #iDeologyCoin

Aat

@aat2024.bsky.social

1 year ago

ACT is The people.🔥🔥🔥🔥🔥🔥💪💪👍

ACT-Acet Token is the people.
acet.finance

#ACT #Acet #ACTWarriors #iHoldACT #ACTisThePeople #iDeologyCoin

StockTitan

@stocktitan.net

1 year ago

#ACET Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

www.stocktitan.net/news/ACET/adicet-opens-e...

StockTitan

@stocktitan.net

1 year ago

#ACET Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

www.stocktitan.net/news/ACET/adicet-bio-ann...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #ACET ) Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

#StockMarket #News

StockTitan

@stocktitan.net

1 year ago

#ACET Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

www.stocktitan.net/news/ACET/adicet-bio-pre...